The Vanguard Group Discloses Investment in Avadel Pharmaceuticals

The Vanguard Group, Inc. has released a Form 8.3 regarding its stake in Avadel Pharmaceuticals plc, in line with the Irish Takeover Panel Act, 1997. The form provides an overview of Vanguard's ownership, highlighting its control over 5,787,815 ordinary shares, equivalent to 5.94% of Avadel's relevant securities, as of January 30, 2026.

The disclosure includes details of recent transactions. Vanguard purchased 2,868 ordinary shares at a price of 21.55 USD and sold 2,920 shares at the same price per unit. No dealings involving cash-settled or stock-settled derivatives have been reported.

No indemnity, option arrangements, or agreements affecting relevant securities have been identified, underscoring a straightforward position disclosure without additional influences impacting their investment strategy in Avadel Pharmaceuticals.